Skip to search formSkip to main contentSkip to account menu

avasimibe

Known as: 2,6-bis(1-methylethyl)phenyl ((2,4,6-tris(1-methylethyl)phenyl)acetyl)sulfamate 
An orally bioavailable inhibitor of acyl-Coenzyme A:cholesterol acyltransferase (ACAT) that prevents cholesterol deposition in the arterial wall… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

AcetatesCytochrome P-450 CYP3A InducersSulfonic Acids

Narrower (1)

CI 1011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Novel 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: dual effectors on acyl-CoA:cholesterol O-acyltransferase and low-density lipoprotein receptor expression.
Highly Cited
2007
Highly Cited
2007
ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.
2006
2006
Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe.
Review
2005
Review
2005
Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.
Acyl-coenzyme A: cholesterol acyltransferase (ACAT) is an intracellular enzyme that catalyzes the formation of cholesterol esters… 
2004
2004
Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
It is now recognized that atherosclerosis complications are related to the unstable character of the plaque rather than its… 
Review
2003
Review
2003
New drugs for the treatment of hypercholesterolaemia
Endogenous and exogenous pathways determine plasma levels of cholesterol and lipoproteins. Plasma cholesterol levels and coronary… 
2003
2003
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
Review
2002
Review
2002
Avasimibe Pfizer.
Avasimibe (also known as CI-1011 or PD-148515) is a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitory… 
2002
2002
Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase…
Review
2001
Review
2001
Therapies on the horizon for cholesterol reduction
Summary: Statins are powerful agents for the reduction of low‐density lipoprotein cholesterol (LDL‐C) and reduction of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)